上海市社科联 2026 学术合作项目

                                             科学食膳 赋能健康

                          第三届“饮食营养与健康专家论坛暨营养与疾病防治”学术会议

                          食材开发应用与药食同源健康产品出海的发展方向

                                              食材开发应用与药食同源健康产品出海的发展方向

                                       中欧一带一路药食同源健康产业研究院   姜海涛

【关键词】药食同源 一带一路 国际标准 健康产业 疾病干预 国际化

【论述研讨】全球慢性病高发，各国越来越重视膳食营养在慢病预防、疾病非药物干预中的价值，“Food

is Medicine”（食物即药物）理念在国际社会广泛传播。欧美、东南亚市场对天然植物膳食产品需求快速增长，为我国药食同源食材与健康产品出海创造市场窗口。

一、我国拥有国家药食同源目录，道地食材资源丰富，生物萃取、酶解、膜分离等现代加工技术日趋成熟，已经形成从原料种植、精深加工到终端产品的完整产业链。依托中欧一带一路药食同源健康产业研究院平台，开展中外产业交流，推动药食同源从国内食材资源优势转化为国际市场竞争优势。

二、国内药食同源目录不等于国际准入资质，国内食品标准不等于海外监管标准，很多产品仍停留在原料初级出口阶段，高附加值成品出海占比不高，面临监管壁垒、循证证据不足、文化认知差异等多重障碍。

三、不同国家监管体系差异巨大，国内 SC 生产许可、药食同源目录不能直接获得海外市场准入资格。

四、欧盟市场：部分药食同源原料属于“新食品（Novel Food）”，需要完成复杂安全评估审批，对农残、重金属限量标准严格；禁止中医传统功效表述，只有经过 EFSA 审批的健康声称才允许使用。

五、北美市场、需要完成 FDA 企业注册、新膳食成分（NDI）申报，产品只能使用结构‑功能声称，严禁治疗疾病宣传。

六、东南亚、大洋洲市场、各国准入规则不一，需要完成原料备案、标签本地化、植物检疫等一系列手续。

七、国内产品配方、口味、剂型主要适配中国消费者，海外市场偏好软糖、粉剂、便携小包装等形态，海外人群饮食结构、体质特点与国内存在差异，直接输出国内配方容易水土不服。

【总结】“药食同源、治未病、辨证施膳”等东方传统概念，海外消费者、监管机构难以理解。如果直接使用中医传统术语，面临下架、处罚风险。同时也突出了“国际疾病非药物干预科学应用联盟”成立的审时度势，需要把传统食养理念转化为科学的现代营养学、预防医学、疾病非药物干预的国际通用术语。以及生产体系对标国际 GMP 标注，完善生产记录、检测报告，满足海外进口商的审核要求。

                                                                      地址：上海食文化研究会会议室   会议时间：2026 年 9 月 17 日

Shanghai Social Science Federation 2026 Academic Cooperation Project

Scientific diet empowers health

The 3rd "Diet, Nutrition and Health Expert Forum and Nutrition and Disease Prevention and

Control" Academic Conference

The development direction of food development and application of health products of the same

origin as medicinal food to go abroad

China-Europe Belt and Road Initiative Medicine and Food Health Industry Research Institute

Jiang Haitao

【Abstract】With the rise of non-drug intervention in global diseases, especially the establishment ofthe "International Alliance for the Scientific Application of Non-drug Interventions in Diseases" inParis, France in 2025, natural diet, medicinal food and the same source as China's characteristic healthindustry resources, have rich local food reserves and mature modern processing technology. Atpresent, there are still real bottlenecks such as low raw material development level, insufficientinternational standard docking, different standards, prominent compliancerisks,andproducthomogenisation in  China's medicinal and food products from overseas. Based on the perspective ofthe China-Europe Belt and Road International Cooperation Platform, this report systematically analyses the current situation of the development and application of medicinal food ingredients of the same origin, and analyses the opportunities and practical challenges faced by products to go abroad, focussing on the six dimensions of source food development, modern technology transformation, product innovation iteration, international compliance adaptation, standard mutual recognition, brand and channel construction. , put forward the layered, compliant and localised overseas development path, and provide academic reference for the high-quality international development of China's medicinal food health industry.

【Keyword】Medicine and food are of the same origin, Belt and Road Initiative, international standards, health industry, disease intervention, internationalisation

【Discussion】With the high incidence of chronic diseases in the world, countries pay more and more attention to

the value of dietary nutrition in the prevention of chronic diseases and non-drug intervention in diseases. The concept of "Food is Medicine" is widely spread in the international community. The demand for natural plant meal products in the European, American and Southeast Asian markets is growing rapidly, creating a market window for China's medicinal food ingredients and health products to go abroad.

I. China has a national catalogue of medicinal food sources, rich in local food resources, and modern processing technologies such as biological extraction, enzymatic lysis and membrane separation are becoming more and more mature. It has formed a complete industrial chain from raw material planting, in-depth processing to terminal products. Relying on the platform of the China-Europe Belt and Road Initiative of the Medicine and Food Health Industry Research Institute, carry out Sino-foreign industry exchanges, and promote the transformation of the advantages of medicinal food resources from domestic ingredients to competitive advantages in the international market.

II. The domestic medicinal food catalogue is not equal to the international access qualification, and the domestic food standards are not equal to the overseas regulatory standards. Many products are still in the primary export stage of raw materials, and the proportion of high-value-added finished products going abroad is not high, facing multiple obstacles such as regulatory barriers, insufficient evidence-based evidence, and cultural perception differences.

III. The regulatory systems of different countries are very different, and the domestic SC production license and the catalogue of medicine and food of the same origin cannot directly qualify for overseas market access.

IV. EU market: Some medicinal and food homo-sourced raw materials belong to "Novel Food", which needs to complete complex safety assessment and approval, and strict standards for agricultural residues and heavy metals; traditional efficacy expressions of traditional Chinese medicine are prohibited, and only health claims approved by EFSA are allowed to be used.

V. In the North American market, it is necessary to complete the FDA enterprise registration and the declaration of new dietary ingredients (NDI). Products can only use structural-function claims, and it is strictly forbidden to publicise the treatment of diseases.

VI. The access rules of Southeast Asian and Oceania markets and countries are different, and it is necessary to complete a series of procedures such as raw material filing, label localisation and plant quarantine.

VII. The formula, taste and dosage form of domestic products are mainly suitable for Chinese consumers. Overseas markets prefer soft candy, powder, portable small packaging and other forms. The diet structure and physical characteristics of overseas people are different from those in China, and it is easy to export domestic formulas directly.

【Summary】It is difficult for overseas consumers and regulatory authorities to understand the traditional oriental concepts such as "the same origin of medicine and food, the treatment of diseases, and the discrimination of food". If you directly use traditional Chinese medicine terms, you will face the risk of being removed from the shelves and punished. At the same time, it also highlights the need to transform the traditional nutrition concept into the international common term of scientific modern nutrition, preventive medicine, and non-drug intervention in diseases. And the production system is compared with the international GMP labelling, improving production records and

inspection reports, and meeting the audit requirements of overseas importers.

Address: Conference Room of Shanghai Food Culture Research Association Meeting

Time: September 17, 2026

审撰 ：食药物质 健康中国栏目组  愚晏

摄影 ：冯赟超  陈金宝

翻译 ：国际食药物质与健康产业联盟 执行秘书长  孙丽

校对：国际疾病非药物干预科学应用联盟（中国代表处）执行秘书长 吴玲